In October 2016, the following letters were sent to relevant healthcare professionals:
- Flolan (epoprostenol):
(solvent pH 12) available from October 2016, with differences in storage and administration from previous formulation (pH 10.5)
- Teva levothyroxine: reintroduction to market and introduction of new tablet strengths (letter for here
, and for ); see also further information
- Blincyto▼ (blinatumomab):
Article citation: Drug Safety Update volume 10 issue 4, November 2016: 3.
Published 8 November 2016